Editas Medicine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Editas Medicine şirketinin toplam hissedar öz sermayesi $175.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $327.6M ve $151.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$265.09m
Eşitlik	US$175.63m
Toplam yükümlülükler	US$151.93m
Toplam varlıklar	US$327.57m

Son finansal sağlık güncellemeleri

Recent updates

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EDIT 'nin kısa vadeli varlıkları ( $271.1M ) kısa vadeli yükümlülüklerini ( $72.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: EDIT şirketinin kısa vadeli varlıkları ( $271.1M ) uzun vadeli yükümlülüklerini ( $79.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EDIT borçsuzdur.

Borcun Azaltılması: EDIT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EDIT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: EDIT serbest nakit akışı her yıl % 15.9 1.2 yıl yetecek nakit akışına sahip olacaktır.

Editas Medicine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Recent updates

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Price target decreased by 7.1% to US$13.00

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Consensus revenue estimates fall by 13%

New major risk - Revenue and earnings growth

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Insider selling

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies